Sponsored Links
| Dynavax Completes Enrollment Of First Cohort Of Patients In Phase 1b Clinical Trial For Hepatitis B Therapy |
 |
 |
 |
| Medical News - Liver Disease and Hepatitis | |||
|
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that enrollment has been completed for the first of three cohorts of patients receiving DV-601 hepatitis B therapy in a Phase 1b clinical trial. The safety profile of patients in the first cohort met pre-specified criteria for dose escalation and the second cohort has been opened for enrollment... Read more: Liver Disease / Hepatitis News From Medical News Today
|